Released on a WHIM

Abstract

In this issue of Blood, 2 groups (McDermott et al1 and Dale et al2) independently report the results of phase 1 clinical trials using the CXCR4-specific chemokine receptor antagonist plerixafor (Mozobil) to target the hyperfunctional CXCR4 signaling axis in patients with the rare immunodeficiency disease WHIM syndrome.